RAKESH DIXIT
Company: Bionavigen
Job title: CEO & Founder
Bio:
Seminars:
Chair’s Opening Remarks 8:50 am
day: Conference Day Two
Morning Networking Break 10:30 am
day: Conference Day Two
Preclinical to Clinical Translational Pharmacology of ADCs and Combinations 11:00 am
Preclinical models often overpredict ADC clearance and efficacy; clinical translation requires biomarkers and modelling Payload toxicities dominate; humans show lower tolerance than animals; combinations add overlapping risks Preclinical PDXs exaggerate responses; clinical outcomes are limited by heterogeneity and resistanceRead more
day: Conference Day Two
Chair’s Closing Remarks 3:30 pm
day: Conference Day Two
Roundtable Discussion: Subcutaneous vs. UV Dosing: Different Approaches Required for Changing Dosing from a Clinician’s Perspective 1:00 pm
Comparing the patient experience and practical considerations of switching from IV to subcutaneous dosing Understanding how route of administration impacts PK, tolerability, and trial design decisions Exploring what it takes to make the transition between dosing routes work for patients and studiesRead more
day: Conference Day One